Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure

Periodic breathing with central sleep apnoea (CSA) is common in heart failure patients and is associated with poor quality of life and increased risk of morbidity and mortality. We conducted a prospective, non-randomized, acute study to determine the feasibility of using unilateral transvenous phrenic nerve stimulation for the treatment of CSA in heart failure patients. Thirty-one patients from six centres underwent attempted transvenous lead placement. Of these, 16 qualified to undergo two successive nights of polysomnographyone night with and one night without phrenic nerve stimulation. Comparisons were made between the two nights using the following indices: apnoeahypopnoea index (AHI), central apnoea index (CAI), obstructive apnoea index (OAI), hypopnoea index, arousal index, and 4 oxygen desaturation index (ODI4). Patients underwent phrenic nerve stimulation from either the right brachiocephalic vein (n 8) or the left brachiocephalic or pericardiophrenic vein (n 8). Therapy period was (mean SD) 251 71 min. Stimulation resulted in significant improvement in the AHI [median (inter-quartile range); 45 (3959) vs. 23 (1227) events/h, P 0.002], CAI [27 (1138) vs. 1 (05) events/h, P 0.001], arousal index [32 (2042) vs. 12 (927) events/h, P 0.001], and ODI4 [31 (2236) vs. 14 (720) events/h, P 0.002]. No significant changes occurred in the OAI or hypopnoea index. Two adverse events occurred (lead thrombus and episode of ventricular tachycardia), though neither was directly related to phrenic nerve stimulation therapy. Unilateral transvenous phrenic nerve stimulation significantly reduces episodes of CSA and restores a more natural breathing pattern in patients with heart failure. This approach may represent a novel therapy for CSA and warrants further study. ClinicalTrials.gov identifier: NCT00909259.